Curriculum Vitae

Personal information:

1. Full name: Faten Hanna Sliman

2. **Adresse**: Safita, Tartous

3. Family situation: married

4. Place and date of birth : 4/11/1979

5. Nationalty: Syrian

6. Email: Fatensliman@tartous-univ.edu.sy

Fatensliman@yahoo.fr

7. **Phone**: 00963957643362



Education:

Since 2011: Lecturer in Medicinal Chemistry, Faculty of Pharmacy.

2006 – **2010**: Ph.D in Medicinal and pharmaceutical chemistry, Paris XI University, France.

2004-2006: Master 1&2 in medicinal chemistry (de la conception à la qualité de médicaments et autres produits de santé).

2003-2004: Assistant at the Faculty of Pharmacy, Tishreen University.

2001: Bachelor's degree in pharmacy and pharmaceutical chemistry (Tishreen University).

Scientific experience:

2019-2020: Reviewer for international peer review and scientific journal (Asian Journal of Research in Infectious Diseases) and (Journal of Pharmaceutical Research International).

2016-2017: Reviewer for international peer review and scientific journal en molecular modeling domain (*Current Computer-Aided Drug Design, CCADD*).

Since 2017: Lecturer at the Faculty of Pharmacy, University of Tartous.

Since 2013: Lecturer at the Faculty of Pharmacy, Al-Hawash Private University.

Since 2012: supervisor for several master and doctorate projects, Faculty of Pharmacy, University of Tishreen.

2003-2004: Assistant at the Faculty of Pharmacy, University of Tishreen.

Ademinstrative experience:

Since 2021: Vice-dean for scientific affairs, Faculty of Pharmacy, University of Tartous.

Since 2020: Head of department of Pharmaceutical Chemistry and Qualty Control, Faculty of Pharmacy, University of Tartous.

Since 2018: Vice-dean for scientific affairs, Faculty of Pharmacy, University of Tartous.

Training courses

22/10-02/11/2018: training courses in India «Advanced analytical techniques: Basic principles and application for quality assessment of drugs and pharmaceuticals »

20-22/2/2017: training courses in general requirement for the competence of testing and calibration laboratories « *ISO/IEC 17025:2017*», Tartous

28/11/2008: training stage « *Formation of teammates for first intervention* », CapSecur Conseil Society, Paris.

29/06–07/07/2007: training courses « *Individualization: towards personalized medicines*», 8th ULLA Summer School, in Leiden, the Netherlands.

15/01-31/07/2006: Master 2 stage for six months « Synthesis of photoaffinity probes for the identification of the site active of integrase IN of the HIV-1» Paris XI, France

01/07-31/07/2005: Master 1 stage in organic synthesis « *Synthèse d'un brin pseudopeptidique* » Paris XI University, France.

01/06-31/06/2005: Master 1 stage in organic synthesis « Synthèse stéréosélective d'une sous unité (22) intermédiaire dans la synthèse de la 17-thiaæstrone » Paris XI University, France.

2001-2003: Pharmacist in my private pharmacy.

Scientific Conferences:

- **4-5/10/2018:** Lecturer at the conference of the pharmaceutical sciences, Al-Baaths University « *Discovery and development of novel anticancer agents* »
- 6/5/2018: Lecturer at the conference of the pharmaceutical sciences, Al-Andalous University « *P53 protein as therapeutic target in Cancer Diseases* »
- 8-10/05/2016: Lecturer at the scientific meeting, Tishreen University « Molecular Modeling for discovery & design of targeted cancer therapy »
- 8-9/10/2015: Lecturer at the conference of the pharmaceutical sciences, Al-Hawash University « Molecular Modelling & Computer Aided Drug Design for cancer treatment»

- 8/04/2015: Lecturer at the scientific meeting, Tishreen University « & Computer Aided Drug Design »
- 23/04/2014: C at the scientific conference, Tishreen University « Drug discovery & development»
- Between 2012 and 2013: Participation at the scientific meetings, Tishreen university.
- 02/05/2010: Participation at the scientific meeting, Paris XI University, France, Poster « Conception, synthèse et évaluation biologique de nouveaux ligands hétérocycliques de la sérine /thréonine kinase Pim-1 ».
- 10/09/2009: Lecturer at the scientific conference BioCIS, Paris XI University, France «Conception, synthèse et évaluation biologique de nouveaux ligands hétérocycliques de la sérine /thréonine kinase Pim-1 »
- 2007: Participation at the doctorate conference, Paris XI University, France, Poster «Synthesis of photoaffinity probes for the identification of the site active of integrase IN of the HIV-1»

Supervisor of doctorate and Master projects:

- 1) Master project of Ms Nidaa Moussa "Control and evaluation the bactericidal effect of Povidone-Iodine solutions common in the local market", Faulty of Pharmacy, Tishreen University, 2016.
- 2) Master project of Mr Hussam Abd Al Ghani "Pharmacophore modeling, virtual screening and molecular docking studies for the discovery of novel CDK2 inhibitors", Faulty of Pharmacy, Tishreen University, 2016.
- 3) Master project of Mme Kinana Hamdan "Enhancement of dissolution rate of ibuprofen from prepared capsules", Faulty of Pharmacy, Tishreen University, 2018.
- 4) Master project of Ms Samar Alnukari "Development of New Src Inhibitors", Faulty of Pharmacy, Tishreen University, 2019.
- 5) Master project of Mr Zen khdar "Design and synthesis of new Serine/Threonine kinase Pim-1 inhibitors", Faulty of Pharmacy, Tishreen University, 2020.
- 6) Master project of Ms Rasha Kattoub, *Development of selective heterocyclic Akt1 inhibitors*", Faulty of Pharmacy, Tishreen University, 2021.
- 7) Master project of Ms Dima Deeb "Synthesis of reduced graphene oxide using green reductants", Faulty of Pharmacy, Tishreen University, 2021.
- 8) Master project of Ms Marah Mohammad "Using derivative spectrophotometry to study the bioequivalence of the amoxicillin and clavonic acid preparations available in the Syrian market", Faulty of Pharmacy, Tishreen University, in process.
- 9) Master project of Mr Muhamad Nanaa "Build a QSAR model for developing novel c-SRC tyrosine kinase inhibitors", Faulty of Pharmacy, Tishreen University, in process.
- 10) Master project of Mr Ali Mhammad "Using FT-IR for Quality Control of a compination of Antihypertensives and Diuretic", Faulty of Pharmacy, Aleppo University, in process.

11) Ph.D project of Mme Amar Issa "Design, synthesis and impurity profile study of new CDK2 inhibitors as suggested anti-cancer drugs", Faulty of Pharmacy, Damascus University, in process.

Teaching modules:

- 1) Pharmaceutical Chemistry (1 & 2).
- 2) Medicinal Chemistry
- 3) Drug synthesis
- 4) Drug Design (Master in Tishreen University)

International & National Publications:

- 1) F. Sliman, D. Desmaële, Synthesis of 5-Aryl- and 5-Heteroaryl-7-carboxyl-8-hydroxyquinaldines through Suzuki Cross-Coupling Reaction with Potassium Organotrifluoroborates. Synthesis 2010, 4, 619 630.
- 2) F. Sliman, M. Blairvacq, E. Durieu, L. Meijer, J. Rodrigo, D. Desmaële. *Identification* and structure-activity relationship of 8-hydroxy-quinoline-7-carboxylic acid derivatives as inhibitors, Bioorganic & Medicinal Chemistry Letters, 2010, 20, 2801-2805.
- 3) F. Sliman, Design, synthesis and biological evaluation of new heterocyclic ligands serine-threonine kinase Pim-1 of Pim-1 kinase, Paris 11, 2010.
- 4) P. M. Loiseau, S. Gupta, A. Verma, S. Srivastava, S. K.Puri, F. Sliman, M. N. Bayle, D. Desmaele. *In Vitro Activities of New 2-Substituted Quinolines against Leishmania Donovani*. Antimicrob Agents & Chem. 2011, 1777–1780.
- 5) P. M. Loiseau, S. Gupta, A. Verma, S. Srivastava, S. Puri, F. Sliman, M. Normand-Bayle, D. Desmaele. *In Vitro Activity against Leishmania donovani of new 2-Substituted Quinolines*, Antimicrobial Agents and Chemotherapy, 2011, 1-12.
- 6) N. Moussa, F. Sliman, Y. Zreik, Control and evaluation the bactericidal effect of Povidone-Iodine solutions common in the local market, Tishreen University Journal for Research and Scientific Studies Health Sciences Series, 2015, 37, 6, 137-147.
- 7) H. A. Ghani, F. Sliman, Pharmacophore modeling, virtual screening and molecular docking studies for the discovery of novel CDK2 inhibitors, Int. J. Pharm. Sci. Res. 2018, 50, 25-33.
- 8) K. Hamdan, F. Sliman, W. Ibrahim, Enhancement of dissolution rate of ibuprofen from prepared capsules, Research J. Pharm. and Tech. 2018, 50, 25-33.
- 9) S. Alnukari, F. Sliman, *Development of New Src Inhibitors*, *Research J. Pharm. and Tech.*, 2019, 12(6):2999-3006.
- 10) Z. A. Khdar, F. Sliman, M. Kousara, *Design and In-Silico ADMET Analysis of new Benzopyrane-derived Pim-1 Inhibitors*, *Research J. Pharm. and Tech.* 2019; 12(11):5413-5423.

- 11) A Issa, F Sliman, J Harbali, Pharmacophore Based Virtual Screening for Identification of Novel CDK2 Inhibitors, International Journal of Organic Chemistry, 2021, 11 (2), 72-89.
- 12) RG Kattoub, F Sliman, M Kousara, Development of Novel Benzimidazole Derivates as Potent and Selective Akt Kinase Inhibitors Using In-silico Approaches, International Journal of Organic Chemistry, 2021, 11 (3), 106-127.
- 13) M Kousara, F Sliman, D Depp, Determination of the free radical scavenging activity of the aqueous extracts of some abundant plants in the Syrian coast in order to use as reductants in green chemistry, Tishreen University Journal-Medical Sciences Series, 2021, 43 (6), 269-283.
- 14) A Issa, F Sliman, J Harbali, Molecular modelling of new CDK2 Inhibitors lead compounds as potential anticancer agents, Damascus University Journal for Health sciences, 2022, Accepted Manuscript.

Lenguages:

Arabic (maternal tongue), English, French
